¹⁸F-Fluorocholine PET/CT as an Imaging Biomarker in Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.

IF 1.7 4区医学 Q4 ONCOLOGY Anticancer research Pub Date : 2025-03-01 DOI:10.21873/anticanres.17514

Wonseok Whi, Hyunjong Lee, Jung Yong Hong, Wonseok Kang, Young Seok Cho, Seung Hwan Moon, Joon Young Choi, Kyung-Han Lee, Seung Hyup Hyun

{"title":"18F-Fluorocholine PET/CT as an Imaging Biomarker in Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.","authors":"Wonseok Whi, Hyunjong Lee, Jung Yong Hong, Wonseok Kang, Young Seok Cho, Seung Hwan Moon, Joon Young Choi, Kyung-Han Lee, Seung Hyup Hyun","doi":"10.21873/anticanres.17514","DOIUrl":null,"url":null,"abstract":"Background/aim: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, and treatment outcomes for advanced disease remain suboptimal. Immunotherapy, particularly atezolizumab plus bevacizumab, has shown promise in improving survival. This study aimed to evaluate the prognostic value of 18F-fluorocholine positron emission tomography/computed tomography (FCH PET/CT) in patients with unresectable HCC undergoing this combination therapy.Patients and methods: This prospective study included 29 patients with unresectable HCC treated with atezolizumab plus bevacizumab. All participants underwent FCH PET/CT prior to treatment. The tumor-to-liver ratio (TLR) of FCH uptake was calculated and analyzed as a potential prognostic biomarker. Progression-free survival (PFS) was assessed using Kaplan-Meier analysis, and Cox proportional hazards models evaluated associations between TLR and clinical outcomes.Results: Patients with higher TLR values of FCH uptake (cutoff: 1.36) demonstrated significantly shorter PFS compared to those with lower TLR values (hazard ratio=4.29, p=0.032). Other clinical variables, including age, sex, tumor size, and viral hepatitis status, were not significantly associated with PFS.Conclusion: TLR of FCH uptake is a valuable non-invasive biomarker for predicting PFS in unresectable HCC patients treated with immunotherapy.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 3","pages":"1273-1280"},"PeriodicalIF":1.7000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17514","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, and treatment outcomes for advanced disease remain suboptimal. Immunotherapy, particularly atezolizumab plus bevacizumab, has shown promise in improving survival. This study aimed to evaluate the prognostic value of ¹⁸F-fluorocholine positron emission tomography/computed tomography (FCH PET/CT) in patients with unresectable HCC undergoing this combination therapy.

Patients and methods: This prospective study included 29 patients with unresectable HCC treated with atezolizumab plus bevacizumab. All participants underwent FCH PET/CT prior to treatment. The tumor-to-liver ratio (TLR) of FCH uptake was calculated and analyzed as a potential prognostic biomarker. Progression-free survival (PFS) was assessed using Kaplan-Meier analysis, and Cox proportional hazards models evaluated associations between TLR and clinical outcomes.

Results: Patients with higher TLR values of FCH uptake (cutoff: 1.36) demonstrated significantly shorter PFS compared to those with lower TLR values (hazard ratio=4.29, p=0.032). Other clinical variables, including age, sex, tumor size, and viral hepatitis status, were not significantly associated with PFS.

Conclusion: TLR of FCH uptake is a valuable non-invasive biomarker for predicting PFS in unresectable HCC patients treated with immunotherapy.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

18f -氟胆碱PET/CT作为肝细胞癌患者接受阿特唑单抗加贝伐单抗的成像生物标志物

背景/目的：肝细胞癌（HCC）是世界范围内癌症相关死亡的主要原因，晚期疾病的治疗结果仍然不理想。免疫治疗，特别是atezolizumab加贝伐单抗，已经显示出改善生存率的希望。本研究旨在评估18f -氟胆碱正电子发射断层扫描/计算机断层扫描（FCH PET/CT）在接受这种联合治疗的不可切除HCC患者中的预后价值。患者和方法：这项前瞻性研究包括29例不可切除的HCC患者，使用阿特唑单抗加贝伐单抗治疗。所有参与者在治疗前都进行了FCH PET/CT检查。计算并分析FCH摄取的肿瘤与肝脏比率（TLR）作为潜在的预后生物标志物。使用Kaplan-Meier分析评估无进展生存期（PFS）， Cox比例风险模型评估TLR与临床结果之间的关系。结果：与TLR值较低的患者相比，FCH摄取TLR值较高的患者（截止值：1.36）的PFS明显较短（风险比=4.29,p=0.032）。其他临床变量，包括年龄、性别、肿瘤大小和病毒性肝炎状态，与PFS无显著相关。结论：FCH摄取的TLR是一种有价值的非侵入性生物标志物，可用于预测不可切除的肝癌患者免疫治疗后的PFS。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.